Pekin Hardy Strauss Inc. Has $848,000 Stock Position in Biohaven Ltd. (NYSE:BHVN)

Pekin Hardy Strauss Inc. grew its holdings in shares of Biohaven Ltd. (NYSE:BHVN) by 27.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 16,975 shares of the company’s stock after acquiring an additional 3,675 shares during the period. Pekin Hardy Strauss Inc.’s holdings in Biohaven were worth $848,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Algert Global LLC lifted its stake in shares of Biohaven by 337.6% in the third quarter. Algert Global LLC now owns 32,392 shares of the company’s stock worth $1,619,000 after acquiring an additional 24,990 shares during the period. Citigroup Inc. raised its holdings in Biohaven by 125.8% during the 3rd quarter. Citigroup Inc. now owns 119,905 shares of the company’s stock worth $5,992,000 after purchasing an additional 66,801 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Biohaven by 5.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 632,690 shares of the company’s stock worth $31,616,000 after purchasing an additional 32,769 shares during the period. Intech Investment Management LLC bought a new stake in shares of Biohaven in the 3rd quarter valued at $565,000. Finally, KBC Group NV increased its position in shares of Biohaven by 24.5% during the third quarter. KBC Group NV now owns 2,250 shares of the company’s stock worth $112,000 after buying an additional 443 shares during the period. Institutional investors and hedge funds own 88.78% of the company’s stock.

Analyst Ratings Changes

BHVN has been the topic of several recent analyst reports. Royal Bank of Canada dropped their target price on shares of Biohaven from $68.00 to $66.00 and set an “outperform” rating on the stock in a report on Wednesday, November 13th. UBS Group cut their target price on Biohaven from $55.00 to $54.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. Sanford C. Bernstein lifted their target price on Biohaven from $55.00 to $66.00 and gave the stock an “outperform” rating in a report on Tuesday, September 24th. Leerink Partners increased their price target on Biohaven from $55.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. Finally, TD Cowen raised their price objective on shares of Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Thirteen investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Biohaven has an average rating of “Buy” and an average target price of $63.42.

Biohaven Price Performance

Shares of NYSE BHVN opened at $45.59 on Monday. Biohaven Ltd. has a 1 year low of $26.80 and a 1 year high of $62.21. The stock has a market capitalization of $4.61 billion, a P/E ratio of -4.88 and a beta of 1.31. The company has a 50-day moving average price of $49.10 and a 200-day moving average price of $41.10.

Biohaven (NYSE:BHVN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.03). As a group, equities research analysts anticipate that Biohaven Ltd. will post -8.85 earnings per share for the current fiscal year.

Insider Activity

In other Biohaven news, Director Gregory Bailey bought 5,000 shares of Biohaven stock in a transaction dated Tuesday, September 24th. The stock was bought at an average cost of $44.19 per share, with a total value of $220,950.00. Following the completion of the acquisition, the director now directly owns 1,620,071 shares in the company, valued at approximately $71,590,937.49. The trade was a 0.31 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director John W. Childs purchased 21,052 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were acquired at an average price of $47.50 per share, for a total transaction of $999,970.00. Following the completion of the acquisition, the director now directly owns 21,052 shares of the company’s stock, valued at $999,970. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. 16.00% of the stock is currently owned by corporate insiders.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.